Revolutionary Study in Antibody and Bacterial Mediated Immunotoxin for Breast Cancer Treatment
Biomedical Statistics and Informatics
Volume 5, Issue 4, December 2020, Pages: 81-86
Received: Nov. 3, 2020;
Accepted: Nov. 19, 2020;
Published: Dec. 31, 2020
Views 35 Downloads 16
Rajaganapathy Kaliyaperumal, Chromosoft Research Centre, CRC Group, Chennai, Tamil Nadu, India
Yuvaraj Govindarajan, Chromosoft Research Centre, CRC Group, Chennai, Tamil Nadu, India
Dillibabu, Chromosoft Research Centre, CRC Group, Chennai, Tamil Nadu, India
Many of this treatments for Breast cancer (BC-carcinoma), including surgery, radiation, and chemotherapy, haven't been effective in diminishing mortality rates, but bacterial mediated Antibody-immunotoxins has become one in all the best approaches to cancer treatment. Under these exceeding background, the present review, based on increasing mini report on bacterial mediated immunotoxins for breast cancer treatment. Various methodology suggest that, antibody therapies has been an central component in the association of malignant disease. Antibodies be capable of block the tumour growth factors or their specificity receptors and activate the immunological attack on the tumour microenvironment especially in breast cancer cells leads to tumor regression, and are used to deliver payloads such as radioisotopes, cytotoxic drugs or toxins. Immunotoxins are a new class of antitumour agents consisting of tumour selective ligands (generally mono clonal antibodies) linked to highly toxic protein molecules such as non-pathogenic bacterial species or programmed bacteria and take the advantage of the exquisite specificity of antibodies to selectively target drug delivery and the potency of toxins to kill the target cells. Currently, the attenuated bacteria as antitumor agents and vectors for gene directed enzyme prodrug or antibody conjugate therapy or immunotoxin have emerged as potential strategies.
Revolutionary Study in Antibody and Bacterial Mediated Immunotoxin for Breast Cancer Treatment, Biomedical Statistics and Informatics.
Vol. 5, No. 4,
2020, pp. 81-86.
AsmaVafadar, et al.,InSilico Design and Evaluation of scFv-CdtB as a Novel Immunotoxin for Breast Cancer Treatment, (2020) Int J Cancer Manag., 13 (1): e96094, doi: 10.5812/ijcm.96094.
Sørlie, T.; Perou, C. M.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M. B.; van de Rijn, M.; Je_rey, S. S.; et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA (2001), 98, 10869–10874.
Habib, J. G.; O’Shaughnessy, J. A. The hedgehog pathway in triple-negative breast cancer. Cancer Med. (2016), 5, 2989-3006.
Colavito, S. A.; Zou, M. R.; Yan, Q.; Nguyen, D. X.; Stern, D. F. Significance of glioma-associated.
Oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NF_B) pathway. Breast Cancer Res. 2014, 16, 444.
Goel, H. L.; Pursell, B.; Chang, C.; Shaw, L. M.; Mao, J.; Simin, K.; Kumar, P.; Vander Kooi, C. W.; Shultz, L. D.; Greiner, D. L.; et al. GLI1 regulates a novel neuropilin-2/_6_1 integrin based autocrine pathway that contributes to breast cancer initiation. EMBO Mol. Med. 2013, 5, 488–508.
Bieche, I.; Lidereau, R. Genetic alterations in breast cancer. Genes Chromosom. Cancer 1995, 14, 227–251.
Tao, Y.; Mao, J.; Zhang, Q.; Li, L. Overexpression of Hedgehog signaling molecules and its involvement in triple-negative breast cancer. Oncol. Lett. 2011, 2, 995–1001.
Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 2010; 146 (3): 264–75. doi: 10.1016/j.jconrel.2010.04.009.
Liu Y, Xu J, Choi HH, Han C, Fang Y, Li Y, et al. Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer. Nat Commun. 2018; 9 (1): 4718. doi: 10.1038/s41467-018-07264-0.
Pernas S, Tolaney SM. HER2-positive breast cancer: New therapeutic frontiers and overcoming resistance. TherAdv Med Oncol. 2019; 11: 1.7588359198335E+15. doi: 10.1177/1758835919833519.
Cunningham A F, Khan M, Ball J, et al. Responses to the soluble flagellar protein FliC are Th2, while those to FliC on Salmonella are Th1. Eur J Immunol. 2004; 34: 2986-95.
Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006; 124: 783-801.
Alaniz R C, Cummings L A, Bergman M A, et al. Salmonella typhimurium coordinately regulates FliC location and reduces dendritic cell activation and antigen presentation to CD4+ T cells. J Immunol. 2006; 177: 3983-93.
Munoz N, Van Maele L, Marques J M, et al. Mucosal administration of flagellin protects mice from Streptococcus pneumoniae lung infection. Infect Immun. 2010; 78: 4226-33.
Nempont C, Cayet D, Rumbo M, et al. Deletion of flagellin'shypervariable region abrogates antibody-mediated neutralization and systemic activation of TLR5-dependent immunity. J Immunol. 2008; 181: 2036-43.
Souzaki, M.; Kubo, M.; Kai, M.; Kameda, C.; Tanaka, H.; Taguchi, T.; Tanaka, M.; Onishi, H.; Katano, M. Hedgehog signaling pathway mediates the progression of non-invasive breast cancer to invasive breast cancer. Cancer Sci. 2011, 102, 373–381.
LanariC,Wargon V, Rojas P, Molinolo AA. Antiprogestins in breast cancer treatment: Are we ready? EndocrRelat Cancer. 2012; 19 (3): R35–50. doi: 10.1530/ERC-11-0378.
Li SG, Li L. Targeted therapy in HER2-positive breast cancer. Biomed Rep. 2013; 1 (4): 499–505. doi: 10.3892/br.2013.95.
Allahyari H, Heidari S, Ghamgosha M, Saffarian P, Amani J. Immunotoxin: A new tool for cancer therapy. Tumour Biol. 2017; 39 (2): 1.0104283176922E+15. doi: 10.1177/1010428317692226.
Sokolova E, Guryev E, Yudintsev A, Vodeneev V, Deyev S, Balalaeva I. HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosis. Oncotarget. 2017; 8 (13): 22048–58. doi: 10.18632/oncotarget.15833.
Raja SM, Desale SS, Mohapatra B, Luan H, Soni K, Zhang J, et al. Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition. Oncotarget. 2016; 7 (9): 10522–35. doi: 10.18632/oncotarget.7231.
Guerra L, Teter K, Lilley BN, Stenerlow B, Holmes RK, Ploegh HL, et al. Cellular internalization of cytolethal distending toxin: A new end to a known pathway. Cell Microbiol. 2005; 7 (7): 921–34. doi: 10.1111/j.1462-5822.2005.00520.x.
Takahashi S, Nakagawa T, Banno T, Watanabe T, Murakami K, Nakayama K. Localization of furin to the trans-Golgi network and recycling from the cell surface involves Ser and Tyr residues within the cytoplasmic domain. J Biol Chem. 1995; 270 (47): 28397–401. doi: 10.1074/jbc.270.47.28397.
Weldon JE, Skarzynski M, Therres JA, Ostovitz JR, Zhou H, Kreitman RJ, et al. Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A. Bioconjug Chem. 2015; 26 (6): 1120–8. doi: 10.1021/acs.bioconjchem.5b00190.